Impact of a dual glucose‐dependent insulinotropic peptide/ glucagon‐like peptide ‐1 receptor agonist tirzepatide on heart rate among patients with type 2 diabetes: A systematic review and pairwise and network meta‐analysis
Pooled result · Heart rate (pairwise meta-analysis)Result — go to the resultMD 1.82 95% CI 0.75–2.89Authors' conclusion
Our study showed not only that there was a greater increase in heart rate in the TZP group than in the control, GLP-1RA and non-GLP-1RA groups, but also that the 15-mg dose of TZP had the strongest impact on increasing heart rates compared with the other five inventions, with a TZP dose-response impact on heart rate. Further research on the effects of TZP treatment-related increases in heart rate is required.
Study context
- Population
- Adults with T2D in RCTs of tirzepatide (TZP) 5, 10 and 15 mg; mean baseline heart rate 65.2 to 75.7 beats per minute8 articles
- Comparison
- Tirzepatide 5, 10 and 15 mg vs control
- Outcome
- Heart rate
Methodological detailsprospectively registered protocol
- Prospectively registered protocol
Pooled result
Heart rate (pairwise meta-analysis)
MD
1.82
95% CI 0.75–2.89
TZPvs Control
MD 1.82 (95% CI 0.75–2.89)
As reported in the abstract
Further pooled results
| Outcome | MD (95% CI) | |
|---|---|---|
| Heart rate, TZP vs GLP-1 RAs and non-GLP-1 RAs (pairwise)TZPvs GLP-1RAs | 2.29 (1.00–3.59) | |
| Heart rate, TZP vs GLP-1 RAs and non-GLP-1 RAs (pairwise)TZPvs non-GLP-1RAs | 1.58 (0.26–2.91) | |
| Heart rate by TZP dose (pairwise)TZP 5 mgvs TZP 10 mg | −0.97 (−1.79 to −0.14) | |
| Heart rate by TZP dose (pairwise)TZP 5 mgvs TZP 15 mg | −2.57 (−3.79 to −1.35) | |
| Heart rate by TZP dose (pairwise)TZP 10 mgvs TZP 15 mg | −1.5 (−2.38 to −0.82) | |
| Heart rate, TZP 15 mg vs others (network meta-analysis)TZP 15 mgvs TZP 5 mg | 2.53 (1.43–3.62) | |
| Heart rate, TZP 15 mg vs others (network meta-analysis)TZP 15 mgvs TZP 10 mg | 1.44 (0.35–2.53) | |
| Heart rate, TZP 15 mg vs others (network meta-analysis)TZP 15 mgvs GLP-1RAs | 3.46 (1.67–5.25) | |
| Heart rate, TZP 15 mg vs others (network meta-analysis)TZP 15 mgvs Insulin | 2.86 (1.32–4.41) | |
| Heart rate, TZP 15 mg vs others (network meta-analysis)TZP 15 mgvs Placebo | 2.96 (1.36–4.57) | |
| −50510Difference (linear scale) |
Original publication
Impact of a dual glucose‐dependent insulinotropic peptide/ glucagon‐like peptide ‐1 receptor agonist tirzepatide on heart rate among patients with type 2 diabetes: A systematic review and pairwise and network meta‐analysis. Diabetes Obes Metab. Published 20 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →